

Resr. Murat SERİLMEZ

Personal Information

Office Phone: [+90 212 414 2434](tel:+902124142434)

Email: murat.serilmez@istanbul.edu.tr

Web: <https://avesis.istanbul.edu.tr/murat.serilmez>

International Researcher IDs

ORCID: 0000-0001-8502-2505

Publons / Web Of Science ResearcherID: V-6153-2018

ScopusID: 41838

Education Information

Doctorate, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Abd Kanser Biyokimyası Bilim Dalı, Turkey 2011 - 2016

Postgraduate, Istanbul University, Temel Onkoloji Abd, Kanser Biyokimyası, Turkey 2008 - 2011

Undergraduate, Ege University, Faculty Of Science, Biyokimya Bölümü, Turkey 2004 - 2008

Foreign Languages

English, B2 Upper Intermediate

Dissertations

Doctorate, AKCİĞER KANSERLİ HASTALARDA HGF, cMET, EGF ve EGFR PROTEİNLERİ VE BU PROTEİNLERİN mRNA DÜZEYLERİNİN BELİRLENMESİ, Istanbul University, Temel Onkoloji Abd, Kanser Biyokimyası, 2016

Postgraduate, Hepatosellüler Karsinomlu Hastalarda VEGF, IL-6 ve GLİPİKAN-3'ün Klinik Önemi , Istanbul University, Temel Onkoloji Abd, Kanser Biyokimyası Bölümü, 2011

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Biochemistry

Academic Titles / Tasks

Medical Doctor, Istanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2009 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

1. **Can serum matrix metalloproteinase-9 and SMAD-2 levels predict lamina propria invasion in bladder urothelial carcinoma?**

Yitgin Y., Erdem S., Serilmez M., Duranyıldız D., Verep S., Gasimov K., Tefik T., Sanli O., Ozcan F.

International Journal of Clinical Practice, vol.75, no.8, 2021 (SCI-Expanded)

- II. **Circulating annexin A2 as a biomarker in patients with pancreatic cancer.**
Karabulut M., Afsar C. U., Serilmez M., Karabulut S.
Journal of cancer research and therapeutics, vol.16, 2020 (SCI-Expanded)
- III. **Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma**
Çavuş B., Akyuz F., İliaz R., Akyuz U., Duranyıldız D., Serilmez M., Tekin D., Evirgen S., Karaca Ç., Demir K., et al.
Experimental Oncology, vol.42, no.3, pp.208-214, 2020 (SCI-Expanded)
- IV. **Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?**
Erturk K., Karaman S., Dagoglu N., Serilmez M., Duranyildiz D., Tas F.
WIENER KLINISCHE WOCHENSCHRIFT, vol.131, pp.419-426, 2019 (SCI-Expanded)
- V. **The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer**
Ucuncu M., Serilmez M., Sari M., Bademler S., Karabulut S.
BIOMOLECULES, vol.9, no.9, 2019 (SCI-Expanded)
- VI. **Serum IL-17 levels can be diagnostic for gastric cancer.**
Karabulut M., Afsar C. U., Serimez M., Karabulut S.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.24, no.4, pp.1601-1609, 2019 (SCI-Expanded)
- VII. **Diagnostic and Prognostic Significance of Carboxypeptidase A4 (CPA4) in Breast Cancer**
Bademler S., Ucuncu M. Z., Yasasever C., Serilmez M., Ertin H., Karanlık H.
BIOMOLECULES, vol.9, no.3, 2019 (SCI-Expanded)
- VIII. **Serum IL-17 levels can be diagnostic for gastric cancer**
Karabulut M., Usul Afşar Ç., Serilmez M., Karabulut S.
Journal Of Buon, vol.24, no.4, pp.1-9, 2019 (SCI-Expanded)
- IX. **Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy**
Serilmez M., Ozgur E., Karaman S., Gezer U., Duranyildiz D.
CANCER BIOMARKERS, vol.25, no.2, pp.177-184, 2019 (SCI-Expanded)
- X. **SERUM AKT2 LEVELS AS A MARKER FOR LUNG CANCER**
Karaman S., Erturk K., Serilmez M., Duranyildiz D., Oral E. N., Dagoglu N.
ACTA MEDICA MEDITERRANEA, vol.35, no.6, pp.3269-3272, 2019 (SCI-Expanded)
- XI. **Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer**
Afsar C. U., Karabulut M., Karabulut S., Ozal S. T., Cikot M., Serilmez M., Tas F.
BIOMOLECULES, vol.8, no.4, 2018 (SCI-Expanded)
- XII. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer**
BADEMLER S., Sari M., Üçüncü M. Z., SERİLMEZ M., Karabulut S.
Acta Medica Mediterranea, vol.34, no.6, pp.2055-2060, 2018 (SCI-Expanded)
- XIII. **Clinical Significance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients**
Erturk K., Tas F., Serilmez M., Bilgin E., Yasasever V.
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.1383-1387, 2017 (SCI-Expanded)
- XIV. **Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma**
Afsar C. U., Karabulut M., Karabulut S., Alis H., Gonenc M., Dagoglu N., Serilmez M., Tas F.
JOURNAL OF INFECTION AND CHEMOTHERAPY, vol.23, pp.196-200, 2017 (SCI-Expanded)
- XV. **Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma**
Iliaz R., Akyuz U., Tekin D., Serilmez M., Evirgen S., Cavus B., Soydinc H., Duranyildiz D., Karaca C., Demir K., et al.
Arab Journal of Gastroenterology, vol.17, no.4, pp.164-167, 2016 (SCI-Expanded)
- XVI. **Circulating serum levels of angiotensin-1 and angiotensin-2 in nasopharynx and larynx carcinoma patients**

- Guveli M. E., Duranyildiz D., Karadeniz A., Bilgin E., Serilmez M., Soydinc H. O., Yasasever V.
TUMOR BIOLOGY, vol.37, no.7, pp.8979-8983, 2016 (SCI-Expanded)
- XVII. **Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma.**
KARABULUT M., GUNALDI M., ALIS H., AFSAR C., KARABULUT S., Serilmez M., AKARSU C., SEYIT H., AYKAN N. F.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.18, pp.160-71, 2016 (SCI-Expanded)
- XVIII. **Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?**
Erturk K., Tastekin D., Bilgin E., Serilmez M., Bozbey H. U., Sakar B.
BIOMEDICINE & PHARMACOTHERAPY, vol.77, pp.86-91, 2016 (SCI-Expanded)
- XIX. **Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer**
Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.77, no.1, pp.127-131, 2016 (SCI-Expanded)
- XX. **Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer**
Erturk K., Tastekin D., Serilmez M., Bilgin E., Bozbey H. U., Vatansever S.
TUMOR BIOLOGY, vol.37, no.1, pp.405-412, 2016 (SCI-Expanded)
- XXI. **CLINICAL SIGNIFICANCE OF SERUM HEPATOCYTE GROWTH FACTOR (HGF) AND ITS RECEPTOR CMET LEVELS IN COLORECTAL CANCER PATIENTS**
KARABULUT M., ALIS H., GUNALDI M., AFSAR C. U., Karabulut S., KONES O., SEYIT H., Serilmez M., Aykan N. F.
ACTA MEDICA MEDITERRANEA, vol.32, no.1, pp.179-187, 2016 (SCI-Expanded)
- XXII. **Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma**
Sen F., Yildiz I., Odabas H., Tambas M., Kilic L., Karadeniz A., Altun M., Ekenel M., Serilmez M., Duranyildiz D., et al.
TUMOR BIOLOGY, vol.36, pp.1039-1044, 2015 (SCI-Expanded)
- XXIII. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.**
Kilic L., Yildiz I., Sen F. K., ERDEM M. G., Serilmez M., Keskin S., Ciftci R., Karabulut S., ORDU C., Duranyildiz D., et al.
Cancer biomarkers : section A of Disease markers, vol.15, no.4, pp.405-11, 2015 (SCI-Expanded)
- XXIV. **The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer**
Karabulut S., Tas F., Tastekin D., KARABULUT M., Yasasever C., Ciftci R., Guveli M., Fayda M., Vatansever S., Serilmez M., et al.
TUMOR BIOLOGY, vol.35, no.9, pp.8849-8860, 2014 (SCI-Expanded)
- XXV. **Clinical significance of serum tenascin-C levels in breast cancer**
Tastekin D., Tas F., Karabulut S., Duranyildiz D., Serilmez M., Guveli M., Vatansever S.
TUMOR BIOLOGY, vol.35, no.7, pp.6619-6625, 2014 (SCI-Expanded)
- XXVI. **Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.4, pp.3327-3331, 2014 (SCI-Expanded)
- XXVII. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.4, pp.3125-3132, 2014 (SCI-Expanded)
- XXVIII. **Clinical significance of serum transforming growth factor-beta 1 (TGF-beta 1) levels in patients with epithelial ovarian cancer**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.4, pp.3611-3616, 2014 (SCI-Expanded)
- XXIX. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion**

molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY, vol.35, no.4, pp.3095-3102, 2014 (SCI-Expanded)

- XXX. **Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer**
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.3, pp.631-637, 2014 (SCI-Expanded)
- XXXI. **Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma**
Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O., Vatansever S., Yasasever V.
TUMOR BIOLOGY, vol.35, no.3, pp.2327-2333, 2014 (SCI-Expanded)
- XXXII. **Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma**
Karabulut S., Duranyildiz D., Tas F., Gezer U., Akyuz F., Serilmez M., Ozgur E., Yasasever C. T., Vatansever S., Aykan N. F.
TUMOR BIOLOGY, vol.35, no.3, pp.2729-2739, 2014 (SCI-Expanded)
- XXXIII. **Clinical significance of serum M30 and M65 levels in melanoma**
Tas F., Karabulut S., Serilmez M., Yildiz I., Sen F., Ciftci R., Duranyildiz D.
MELANOMA RESEARCH, vol.23, no.5, pp.390-395, 2013 (SCI-Expanded)
- XXXIV. **Clinical and prognostic significance of coagulation assays in gastric cancer.**
Tas F., Ciftci R., Kilic L., Serilmez M., Karabulut S., Duranyildiz D.
Journal of gastrointestinal cancer, vol.44, pp.285-92, 2013 (SCI-Expanded)
- XXXV. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**
Yildiz I., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)
- XXXVI. **Clinical and prognostic significance of coagulation assays in lung cancer**
Tas F., Kilic L., Serilmez M., Keskin S., Sen F., Duranyildiz D.
RESPIRATORY MEDICINE, vol.107, no.3, pp.451-457, 2013 (SCI-Expanded)
- XXXVII. **For Which Cancer Types can Neuron-Specific Enolase be Clinically Helpful in Turkish Patients?**
Bilgin E., Dizdar Y., Serilmez M., Soydinc H. O., Yasasever C., Duranyildiz D., Yasasever V.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.4, pp.2541-2544, 2013 (SCI-Expanded)
- XXXVIII. **Immobilization and stabilization of alpha-galactosidase on Sepabeads EC-EA and EC-HA**
Bayraktar H., Serilmez M., Karkas T., Celem E. B., ÖNAL S.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol.49, no.4, pp.855-860, 2011 (SCI-Expanded)
- XXXIX. **Hematological parameters in lung cancer Akciğer kanserinde hematolojik parametreler**
SERİLMEZ M., Oğuz H. O., ÇAMLICA H., TOPUZ E., DURANYILDIZ D.
Turk Onkoloji Dergisi, vol.25, no.3, pp.87-92, 2010 (SCI-Expanded)

Articles Published in Other Journals

- I. **Nectin-2 and Nectin-4 Adhesion Molecules in Patients with Breast Cancer**
Ak N., Serilmez M., Ucuncu M. Z., Bademler S., Vatansever S.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.36, no.2, pp.165-170, 2021 (ESCI)
- II. **Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma**
Serilmez M., Akyuz F., Ormeci Ciftcibasi A., Karabulut S., Kaymakoglu S., Yasasever V., Duranyildiz D.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.33, no.1, pp.18-27, 2018 (ESCI)
- III. **Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma**
Erturk K., Tas F., Serilmez M., Bilgin E., Duranyildiz D.

MOLECULAR AND CLINICAL ONCOLOGY, vol.8, no.1, pp.204-208, 2018 (ESCI)

- IV. **Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma**
Karabulut S., Afsar C. U., Karabulut M., Alis H., Bozkurt M. A., Aydogan F., Serilmez M., Tas F.
BBA CLINICAL, vol.6, pp.138-142, 2016 (ESCI)
- V. **Is serum tenascin-C level potential biomarker in pancreatic adenocarcinoma?**
Karabulut S., KARABULUT M., ALIS H., Tambas M., KAPAN S., KONES O., Karaman S., Serilmez M., Tas F.
MEDICAL JOURNAL OF BAKIRKOY, vol.12, no.2, pp.76-82, 2016 (ESCI)
- VI. **Akciğer Kanserinde Hematolojik Parametreler**
SERİLMEZ M., OĞUZ SOYDİNÇ H., CAMLICA H., TOPUZ E., DURANYILDIZ D.
TÜRK ONKOLOJİ DERGİSİ, vol.25, no.3, pp.87-92, 2010 (Scopus)
- VII. **Hematological parameters in lung cancer**
SERİLMEZ M., OĞUZ SOYDİNÇ H., Camlica H., Topuz E., DURANYILDIZ H. D.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.25, no.3, pp.87-92, 2010 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **Tensin-2 Molekülünün Meme Kanseri Hastalarındaki Önemi**
YASASEVER C. T., BILGIN E., SERİLMEZ M., OĞUZ SOYDİNÇ H., BADEMLER S., KARANLIK H., TILGEN YASASEVER C., BİLGİN DOĞRU E.
29. Ulusal Biyokimya Kongresi, Muğla, Turkey, 26 - 30 October 2018, pp.1
- II. **Importance of AXL Molecule in Lung Cancers**
Kızır A., Bilgin Doğru E., Tilgen Yasasever C., Serilmez M.
15. İstanbul Üniversitesi Onkoloji Enstitüsü Günleri Sempozyumu ve 8. İstanbul Üniversitesi Onkoloji Enstitüsü Çalıştayı, İstanbul, Turkey, 1 - 02 December 2017, pp.1
- III. **Over Kanseriinde HMGB1 ve IRE1'in Önemi**
BİLGİN DOĞRU E., TILGEN YASASEVER C., SERİLMEZ M., SAİP P. M., YASASEVER F. V.
22. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.159
- IV. **Meme Kanseri Hastalarda TIMP-1, HA ve SPARC Düzeyleri**
Tilgen Yasasever C., Bilgin Doğru E., Serilmez M., Öztürk N., Yasasever F. V.
22. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.162
- V. **Clinical significance of serum cmet and hgf protein and mRNA levels in lung cancer.**
SERİLMEZ M., ÖZGÜR E., KARAMAN Ş., OĞUZ SOYDİNÇ H., DURANYILDIZ D., YASASEVER V.
41st Congress of the Federation of European Biochemical Societies (FEBS), İzmir, Turkey, 3 - 08 September 2016, pp.1
- VI. **Mide Kanseriinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi**
ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., H. U., VATANSEVER S.
3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanseri Tedavileri Kongresi, Antalya, Turkey, 11 - 15 May 2016, pp.1
- VII. **Over Kanseri Hastalarda Prolaktin ve Interlökin-10'un Rolü**
SERİLMEZ M., OĞUZ SOYDİNÇ H., KURU O., DURANYILDIZ D., YASASEVER V.
6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.1
- VIII. **Meme Kanseri Hastalarda NGAL ve MMP-9'un Kemoterapi İle Değişimi**
OĞUZ SOYDİNÇ H., SERİLMEZ M., ŞEN F., DURANYILDIZ D., YASASEVER V.
6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.1
- IX. **Hepatosellüler karsinomda galektin-3 ve fibronektin molekülleri yeni bir tümör belirteci olabilir mi?**
SERİLMEZ M., AKYÜZ M., TAŞTEKİN D., OĞUZ SOYDİNÇ H., DURANYILDIZ D.
21. Ulusal Kanseri Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1
- X. **Meme kanseri hastalarda plazma D-Dimer düzeylerinin tümör yükü ve metastazı ile ilişkisi**
KILIC L., ŞEN F., YILDIZ İ., KESKİN S., EKENEL M., SERİLMEZ M., DURANYILDIZ D., TAŞ F.
4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.250

- XI. **What kind of a role may play IFN-gamma and emmprin in head and neck cancers?**
Bilgin E., Serilmez M., Duranyildiz D., Yasasever V.
36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.197
- XII. **Angiogenesis markers in nasopharynx and larynx cancers**
Serilmez M., Bilgin E., Yasasever V., Duranyildiz D.
36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.233
- XIII. **Baş-Boyun kanserlerinde VEGF-C'nin yeri var mı?**
Serilmez M., BİLGİN E., KARADENİZ A. N., Yıldız I., YASASEVER F. V.
19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1
- XIV. **Kolon ve rektum karsinomlu hastalarda EGFR IL-6 ve IL-10 düzeyleri**
SERİLMEZ M., OĞUZ SOYDİNÇ H., KILIÇ L., UZUNOĞLU S., TAŞ F., DURANYILDIZ D.
19.Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1
- XV. **Mide karsinomlarında sitokin ve epidermal büyüme faktörü (EGFR) düzeyleri**
SERİLMEZ M., OĞUZ SOYDİNÇ H., CİCİN I., UZUNOĞLU S., DURANYILDIZ D.
19.Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1
- XVI. **The levels of plasma fibrinogen in cancer patients**
SERİLMEZ M., OĞUZ SOYDİNÇ H., DURANYILDIZ D.
The 5th APOCP Conference, İstanbul, Turkey, 3 - 07 April 2010, pp.1
- XVII. **Renal function tests in childhood cancer**
OĞUZ SOYDİNÇ H., SERİLMEZ M., YASASEVER V.
The 5th APOCP Conference, İstanbul, Turkey, 3 - 07 April 2010, pp.1
- XVIII. **Platin-bazlı kemoterapi alan hastalarda üre- kreatinin değerleri**
OĞUZ SOYDİNÇ H., SERİLMEZ M., TAŞ F., YASASEVER V.
21. Ulusal Biokimya Kongresi, İstanbul, Turkey, 28 - 31 October 2009, pp.1
- XIX. **Akciğer kanserli hastalarda kemoterapi ve radyoterapinin hematolojik parametreler üzerine etkisi**
SERİLMEZ M., OĞUZ SOYDİNÇ H., TAŞ F., DURANYILDIZ D.
21. Ulusal Biokimya Kongresi, İstanbul, Turkey, 28 - 31 October 2009, pp.1

Supported Projects

VATANSEVER S., BADEMLER S., TILGEN YASASEVER C., KARANLIK H., SERİLMEZ M., BİLGİN DOĞRU E., Project Supported by Higher Education Institutions, Meme Tümörlerinde Nektin2 ve Nektin4 Adezyon Molekülleri, 2017 - 2019

KARANLIK H., TILGEN YASASEVER C., SERİLMEZ M., BİLGİN DOĞRU E., BADEMLER S., OĞUZ SOYDİNÇ H., Project Supported by Higher Education Institutions, Meme Tümörlerinde Tensin2 Molekülü, 2017 - 2018

KIZIR A., SERİLMEZ M., BİLGİN DOĞRU E., TILGEN YASASEVER C., ERTÜRK K., Project Supported by Higher Education Institutions, Akciğer Kanserlerinde AXL Molekülü, 2017 - 2018

KARADENİZ A. N., SERİLMEZ M., KARAMAN Ş., TILGEN YASASEVER C., BİLGİN DOĞRU E., Project Supported by Higher Education Institutions, Baş-Boyun Kanserlerinde DCLK1 Molekülü, 2017 - 2018

BADEMLER S., SERİLMEZ M., BİLGİN DOĞRU E., KARANLIK H., TILGEN YASASEVER C., Project Supported by Higher Education Institutions, Meme Kanserinde CPA4 Seviyesinin Belirlenmesi ve Önemi, 2017 - 2018

DURANYILDIZ H. D., SERİLMEZ M., OĞUZ SOYDİNÇ H., TAŞ F., GEZER U., KIZIR A., Project Supported by Higher Education Institutions, Akciğer Kanserinde LYVE-1'in Önemi, 2015 - 2017

DURANYILDIZ H. D., SERİLMEZ M., Project Supported by Higher Education Institutions, Akciğer Kanserli Hastalarda HGF,cMET,EGF ve EGFR Proteinleri ve Bu Proteinlerin mRNA Düzeylerinin Belirlenmesi, 2014 - 2016

Metrics

Publication: 65

Citation (WoS): 334

Citation (Scopus): 383

H-Index (WoS): 11

H-Index (Scopus): 12